Finance entity
AstraZeneca is most often covered alongside Bristol Myers Squibb, which appears in 2 of these 4 stories. The clearest coverage concentration is markets: 3 of 4 stories, with the rest divided among 1 other category. At 7.5, the average consequence score sits above the same-window beat average of 6.3.
Last mentioned: Aug 3, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
AstraZeneca is most often covered alongside Bristol Myers Squibb, which appears in 2 of these 4 stories. The clearest coverage concentration is markets: 3 of 4 stories, with the rest divided among 1 other category. At 7.5, the average consequence score sits above the same-window beat average of 6.3. That works out to roughly 0.2 stories per week across a 159-day span. Each story carries 2.5 original sources on average, compared with 2.8 for the broader beat in this window. We currently track 4 Finance stories that mention AstraZeneca, published between February 26, 2026 and August 3, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 3307 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AstraZeneca. Shared-story counts are live from our verified record — not editorial picks.
Guidance Issued
The registrar advises companies to document filing errors and promises to take the outage into account for deadlines.
Vulnerability Identified
Dan Neidle of Tax Policy Associates discovers that the 'back' button allows access to other companies' private data.
Agency Alerted
Companies House is formally notified of the security flaw by Tax Policy Associates.
Service Suspension
Companies House takes the WebFiling portal offline on Friday evening to investigate the breach.
AstraZeneca shares plummeted in London trading after reports of merger talks with Bristol Myers Squibb, as the market priced in execution risk, regulatory peril, and potential overpayment for a deal that would create a £300bn giant.
The speculative $400 billion merger would rank among the largest ever, offering BMS stockholders an exit from patent headwinds and giving AZN a US listing boost. However, financing structure and antitrust hurdles present major risks.
The UK’s corporate registrar, Companies House, has taken its WebFiling service offline following the discovery of a critical security flaw that exposed sensitive director data. The vulnerability allowed unauthorized users to view and potentially edit corporate records, raising significant concerns regarding identity theft and corporate fraud.
The FTSE 100 opened significantly higher on Thursday as market analysts officially coined the 'HALO' trade, a new thematic grouping of UK blue-chips. This shift signals a strategic pivot by institutional investors toward London's value-driven giants amid a cooling global interest rate environment.
Source: proactiveinvestors.co.uk · finance.yahoo.com
AstraZeneca is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
